R&D News | pharmaphorum

News

Sanofi gives up on amlitelimab in atopic dermatitis

Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.

News

J&J's multiple myeloma duo aces phase 3 trial

Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.

News

Lilly plans Q1 2027 filing for obesity triple retatrutide

Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.

News

Repligen builds in cell therapy with $1.5bn BioLife takeover

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

News

Kaken details the data behind its PI3K inhibitor filing

Kaken has revealed the data that supported its recent marketing application for serabelisib as a treatment for vascular malformations in Japan.

News

Gilead, MSD share data on once-weekly oral HIV treatment

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.

Sanofi gives up on amlitelimab in atopic dermatitis

J&J's multiple myeloma duo aces phase 3 trial

Lilly plans Q1 2027 filing for obesity triple retatrutide

Repligen builds in cell therapy with $1.5bn BioLife takeover

Kaken details the data behind its PI3K inhibitor filing

Gilead, MSD share data on once-weekly oral HIV treatment

ESMO26: Lowering toxicity, extending lives, with Syncromune

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks